Zealand Pharma A/S - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ZLDPY Over the counter 2830 www.zealandpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Zealand Pharma A/S

Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830 - Oct 18th, 2026 11:00 pm
Stocktwits Biotech Dealmaker: Gilead, AstraZeneca And Roche Chase Pipeline Expansion Over Buyouts - Oct 16th, 2026 5:57 pm
Here are the latest additions to UBS’ ’Pan-European Small & Mid-Cap’ list - Oct 16th, 2026 3:56 am
Zealand Pharma pens $1.2bn AI obesity drug discovery pact with Generate - Oct 14th, 2026 10:17 am
Generate Biomedicines Lands Major AI Drug Partnership to Target Booming Obesity Market - Oct 14th, 2026 9:30 am
Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases - Oct 13th, 2026 2:30 pm
Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases - Oct 13th, 2026 2:30 pm
Has Zealand Pharma (CPSE:ZEAL) Fallen Enough To Look Cheap On Earnings? - Oct 9th, 2026 8:15 pm
Zealand Pharma (CPSE:ZEAL) Could Be 43% Undervalued After Phase 2 Trial Success - Oct 9th, 2026 7:15 pm
FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analysts - Oct 9th, 2026 9:18 am
Zealand Pharma (CPSE:ZEAL) Reports Positive Phase 2 Petrelintide Results In Type 2 Diabetes - Oct 9th, 2026 3:13 am
Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes - Oct 7th, 2026 11:14 am
Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026) - Oct 5th, 2026 10:30 am
Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts - Oct 1st, 2026 7:30 am
Zealand Pharma Reports 13.1% Weight Loss in Phase 3 Survodutide Trial - Oct 1st, 2026 3:29 am
Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes - Oct 1st, 2026 1:30 am
Total number of shares and voting rights in Zealand Pharma as of September 30, 2026 - Sep 30th, 2026 2:00 pm